ABO基因启动子甲基化在肿瘤患者ABO血型抗原表达减弱中的作用和机制的研究进展*

doi:10.3969/j.issn.1671-2587.2025.02.020

临床输血与检验 ›› 2025, Vol. 27 ›› Issue (2): 283-288.DOI: 10.3969/j.issn.1671-2587.2025.02.020

• 综述 • 上一篇

ABO基因启动子甲基化在肿瘤患者ABO血型抗原表达减弱中的作用和机制的研究进展^*

李峣, 史鸣昊, 沈忠军, 王欣, 赵丽艳

吉林大学第二医院输血科,吉林长春 130041

收稿日期:2024-12-01 出版日期:2025-04-20 发布日期:2025-04-17
通讯作者: 赵丽艳,主要从事肿瘤细胞遗传学、肿瘤细胞侵袭转移分子机制、肿瘤合并血栓分子标志物分析、疑难血型与分子诊断等方面研究,（E-mail）zhaoliy@jlu.edu.cn。
作者简介:李峣,主要从事胶质瘤发病机制、血型变异的分子机制方面研究,（E-mail）934914559@qq.com。
基金资助:
*本课题受吉林省科技发展计划项目（No.20240401068YY）、中国高校产学研创新基金项目（No.2023JQ011）共同资助

Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors

LI Yao, SHI Minghao, SHEN Zhongjun, WANG Xin, ZHAO Liyan

Department of Blood Transfusion, the Second Hospital of Jilin University, Jilin Changchun 130041

Received:2024-12-01 Online:2025-04-20 Published:2025-04-17

摘要/Abstract

摘要： ABO血型抗原在许多肿瘤细胞膜上表达,但在一些肿瘤患者中可观察到肿瘤细胞上A和B血型抗原表达减弱的现象,这种现象的发生往往与肿瘤进展相关。ABO血型抗原表达减弱的现象在肿瘤发生发展中出现的机制尚不清楚,近年的研究表明,ABO基因启动子区域CpG岛甲基化状态可能与ABO血型抗原的表达有关。本文旨在对ABO基因启动子甲基化在肿瘤患者发生ABO血型抗原表达减弱现象中的作用及机制作一简要综述。

关键词: ABO血型抗原, CpG岛, 甲基化, 肿瘤

Abstract: ABO blood group antigens are expressed on the membranes of many tumor cells, but in some cancer patients, a weakened expression of A and B blood group antigens on tumor cells can be observed, which is often associated with tumor progression. The role and mechanism of the weakened expression of ABO blood group antigens in the occurrence and development of tumors are still unclear. Recent studies have shown that the methylation status of CpG islands in the promoter region of ABO genes may be related to the expression of ABO blood group antigens. This article aims to provide a brief review of the role and mechanism of ABO genes promoter methylation in the weakened expression of ABO blood group antigens in tumors.

Key words: ABO blood group antigens, CpG islands, Methylation, Cancer

中图分类号:

R730.2R446.6

李峣, 史鸣昊, 沈忠军, 王欣, 赵丽艳. ABO基因启动子甲基化在肿瘤患者ABO血型抗原表达减弱中的作用和机制的研究进展^*[J]. 临床输血与检验, 2025, 27(2): 283-288.

LI Yao, SHI Minghao, SHEN Zhongjun, WANG Xin, ZHAO Liyan. Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(2): 283-288.

参考文献

[1] AYMARD J P.Karl Landsteiner(1868-1943)and the discovery of blood groups[J].Transfus Clin Biol,2012, 19(4/5):244-248.
[2] LEÓN-ATANCE P,MORENO-MATA N,GONZÁLEZ-ARAGONESES F,et al.Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer[J].Arch Bronconeumol,2012, 48(2):49-54.
[3] HAN J H,LEE H,KIM J K,et al.Clinical significance of decreased or loss of ABO blood group expression in acute myeloid leukaemia:a single-centre retrospective study[J].Vox Sang,2024,119(4):353-362.
[4] GAO S,BENNETT E P,REIBEL J,et al.Histo-blood group ABO antigen in oral potentially malignant lesions and squamous cell carcinoma—genotypic and phenotypic characterization[J].APMIS,2004,112(1):11-20.
[5] CHENNA D,MOHAN G,REDDY V R,et al.The disappearance of blood group antigens:a clue to the clinical diagnosis of leukemia[J].Transfus Apher Sci, 2019,58(1):48-49.
[6] VAN LOGHEM J J Jr,DORFMEIER H,VAN DER HART M.Two A antigens with abnormal serologic properties[J].Vox Sang,1957,2(1):16-24.
[7] SHAFIQ M,KARIM F.Red cell antigen loss in a patient with chronic myeloid leukemia:a case of ABO discrepancy[J]. Transfus Apher Sci,2015,52(1):103-104.
[8] CHIHARA Y,SUGANO K,KOBAYASHI A,et al.Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene[J].Lab Invest,2005,85(7):895-907.
[9] DABELSTEEN E,GAO S.ABO blood-group antigens in oral cancer[J].J Dent Res,2005,84(1):21-28.
[10] BHOOTRA S,JILL N,SHANMUGAM G,et al.DNA methylation and cancer:transcriptional regulation, prognostic,and therapeutic perspective[J].Med Oncol, 2023,40(2):71.
[11] SAGHAFINIA S,MINA M,RIGGI N,et al.Pan-cancer landscape of aberrant DNA methylation across human tumors[J].Cell Rep,2018,25(4):1066-1080.e8.
[12] KOMINATO Y,HATA Y,TAKIZAWA H,et al.Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region[J].J Biol Chem, 1999,274(52):37240-37250.
[13] WORM J,KIRKIN A F,DZHANDZHUGAZYAN K N, et al.Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells[J].J Biol Chem,2001,276(43):39990-40000.
[14] PROKHORTCHOUK E,HENDRICH B.Methyl-CpG binding proteins and cancer:are MeCpGs more important than MBDs?[J].Oncogene,2002,21(35):5394-5399.
[15] NAN X,NG H H,JOHNSON C A,et al.Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex[J].Nature,1998, 393(6683):386-389.
[16] CHIU R W K,CHIM S S C,WONG I H N,et al. Hypermethylation of RASSF1A in human and Rhesus placentas[J].Am J Pathol,2007,170(3):941-950.
[17] CHEN R,GAN Q Y,ZHAO S T,et al.DNA methylation of miR-138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2[J].BMC Cancer,2022, 22(1):488.
[18] LE X,MU J H,PENG W Y,et al.DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative/ER stress-mediated apoptosis and pyroptosis[J].Theranostics, 2020,10(21):9495-9511.
[19] BIANCO-MIOTTO T,HUSSEY D J,DAY T K,et al.DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients[J].PLoS One,2009,4(3):e4788.
[20] 邵明,吕先萍,汤平,等.急性白血病ABO抗原减弱患者与抗原正常患者的对比研究[J].中国实验血液学杂志,2017, 25(5):1307-1313.
[21] 宋倩倩,杨爽,郝芊萌,等.急性髓系白血病血型变化及其与治疗效果的关系[J].中国输血杂志,2024,37(6):700-704.
[22] 李军,刘宏旭,李玉,等.ABH及Lewis A组织-血型抗原表达与原发肺腺癌转移和预后的关系[J].中国现代医学杂志,2005,15(5):695-698.
[23] WANG C,ZHOU J J,WANG L L,et al.ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women[J].Cancer Med,2023, 12(6):7498-7507.
[24] ICHIKAWA D,HANDA K,WITHERS D A,et al.Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility:approach with A and B gene transfection[J].Cancer Res,1997,57(15): 3092-3096.
[25] HAHN M A,WU X W,LI A X,et al.Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks[J].PLoS One,2011, 6(4):e18844.
[26] ANSTEE D J.The relationship between blood groups and disease[J].Blood,2010,115(23):4635-4643.
[27] FRANCHINI M,FAVALORO E J,TARGHER G,et al.ABO blood group,hypercoagulability,and cardiovascular and cancer risk[J].Crit Rev Clin Lab Sci,2012,49(4):137-149.
[28] FRANCHINI M,LIPPI G.The intriguing relationship between the ABO blood group,cardiovascular disease,and cancer[J].BMC Med,2015,13:7.
[29] DENTALI F,SIRONI A P,AGENO W,et al.ABO blood group and vascular disease:an update[J].Semin Thromb Hemost,2014,40(1):49-59.
[30] LUND R J,HUHTINEN K,SALMI J,et al.DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer[J].Sci Rep,2017,7(1):1469.
[31] 徐华,鲍国强,王宝燕,等.ABO基因启动子CpG岛甲基化与白血病的相关性[J].中国实验血液学杂志,2008,16(2): 240-246.
[32] 刘静. 部分白血病与骨髓增生异常综合征患者红细胞AH抗原表达与基因启动子CpG岛甲基化研究[D].苏州:苏州大学,2011.
[33] 邵明,汤平,吕先萍,等.ABO血型基因启动子甲基化水平在成人白血病和骨髓增生异常综合征中的临床意义和预后分析[J].中华内科杂志,2018,57(11):816-823.
[34] 邵明. DNA甲基化对白血病ABO基因表达的影响[D].郑州:郑州大学,2017.
[35] MIOLA M P,DE OLIVEIRA T C,GUIMARÃES A A G, et al.ABO discrepancy resolution in two patients with acute myeloid leukemia presenting the transient weak expression of A antigen[J].Hematol Transfus Cell Ther, 2024,46(1):85-88.
[36] YAMAMOTO F.Review:ABO blood group system—ABH oligosaccharide antigens,anti-A and anti-B,A and B glycosyltransferases,and ABO genes[J].Immunohematology,2004,20(1):3-22.
[37] LADD C,BOURKE M T,SCHERCZINGER C A,et al.A PCR-based strategy for ABO genotype determination[J].J Forensic Sci,1996,41(1):134-137.
[38] PRAKASH S,MOHAPATRA S,BHAGAVATHI M S,et al.Loss and reappearance of A antigen after chemotherapy leading to blood group discrepancy in acute myeloid leukemia:a case report[J].Lab Med,2021,52(5):509-513.
[39] SAKAMOTO Y,KAMADA M,IRAHARA M,et al.Differences in clinical significance of blood group antigens A,B,and H in carcinoma tissue in the uterine cervix[J].Gynecol Oncol,1986,25(2):195-203.
[40] GWIN J L,KLEIN-SZANTO A J,ZHANG S Y,et al.Loss of blood group antigen A in non-small cell lung cancer[J].Ann Surg Oncol,1994,1(5):423-427.
[41] 金沙,向东,刘曦,等. 疾病导致ABO血型抗原及抗体减弱的分析[J]. 临床输血与检验,2010,12(1):61-62.
[42] CHOI S J,KIM H K,SUH E J,et al.CEBPA double mutations associated with ABO antigen weakness in hematologic diseases[J].Blood Adv,2024,8(6):1487-1493.
[43] GAO S,WORM J,GULDBERG P,et al.Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma[J].Int J Cancer,2004,109(2):230-237.
[44] NAMBIAR R K,NARAYANAN G,PRAKASH N P,et al.Blood group change in acute myeloid leukemia[J].Proc (Bayl Univ Med Cent),2017,30(1):74-75.
[45] TAMAI M,FUJISAWA S,NGUYEN T T T,et al.Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis[J].Cancer Gene Ther, 2023,30(1):38-50.
[46] YING Y L,TAO S D,HE Y M,et al.Molecular mechanism of an individual with weaken B phenotype in ABO blood group[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2011,28(4):397-400.
[47] 刘静,李志强.部分恶性血液病患者红细胞A、H抗原表达与基因启动子CpG岛甲基化研究[J].临床输血与检验, 2011,13(3):205-211.
[48] 庞辉. 急性白血病致ABO血型变异1例[J]. 临床输血与检验,2012,14(2):183-184.
[49] TAKAHASHI Y,KUBO R,SANO R,et al.Histone deacetylase inhibitors suppress ABO transcription in vitro,leading to reduced expression of the antigens[J].Transfusion,2017,57(3):554-562.
[50] KRONSTEIN-WIEDEMANN R,KÜNZEL S R, THIEL J,et al.Role of MiRNA in the regulation of blood group expression[J].Transfus Med Hemother,2024, 51(4):237-251.
[51] DABELSTEEN E.ABO blood group antigens in oral mucosa.What is new?[J].J Oral Pathol Med,2002,31(2): 65-70.
[52] VIDAL S,BRUYÈRE I,MALLERON A,et al.Non-isosteric C-glycosyl analogues of natural nucleotide diphosphate sugars as glycosyltransferase inhibitors[J].Bioorg Med Chem,2006,14(21):7293-7301.
[53] WANG K Y,HE Z X,JIN G,et al.Targeting DNA methyltransferases for cancer therapy[J].Bioorg Chem, 2024,151:107652.
[54] AUMER T,DÄTHER M,BERGMAYR L,et al.The type of DNA damage response after decitabine treatment depends on the level of DNMT activity[J].Life Sci Alliance,2024, 7(9):e202302437.
[55] NISHIYAMA A,NAKANISHI M.Navigating the DNA methylation landscape of cancer[J].Trends Genet,2021, 37(11):1012-1027.

ABO基因启动子甲基化在肿瘤患者ABO血型抗原表达减弱中的作用和机制的研究进展^*

Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	中国输血协会临床输血管理学专业委员会, 中华医学会血液学分会, 中国药师协会肿瘤药师分会. 靶向药物导致血液系统异常的输血与药物治疗中国专家共识^*[J]. 临床输血与检验, 2025, 27(1): 1-12.
[2]	李国才, 桂嵘, 黄雪原, 屈琳, 周雄辉, 刘凤霞. 湖南省ABO血型分布及其与恶性肿瘤的相关性分析^*[J]. 临床输血与检验, 2025, 27(1): 70-75.
[3]	杨颖, 李子涵, 丁旭苹, 张嘉敏, 李勤, 郭忠慧, 赵俸涌, 杨启修, 王晨, 路丽明, 朱自严. 肿瘤抗原肽的HLA限制性确认和诱导反应性T细胞杀瘤能力评估^*[J]. 临床输血与检验, 2024, 26(4): 433-439.
[4]	周仁龙, 李凌波, 闫岩, 唐丹丹. 血型CD36基因在泛癌中的综合分析[J]. 临床输血与检验, 2024, 26(2): 251-261.
[5]	李洋, 杨明峰, 王莹, 张坚, 刘嘉馨, 孙保亮. 血红蛋白类氧载体的研究进展及应用前景^*[J]. 临床输血与检验, 2024, 26(2): 282-288.
[6]	郭彬瀚, 叶萍, 陈剑, 凤婧, 江咏梅. 基于生物信息学探究红细胞储存时间对子宫内膜癌的影响[J]. 临床输血与检验, 2023, 25(6): 789-797.
[7]	芮雪, 蔡杰, 刘春都, 傅强, 张春, 何成涛. 肿瘤患者多次输血引起的联合抗体的鉴定策略分析——附1例报道[J]. 临床输血与检验, 2023, 25(6): 839-844.
[8]	杨颖, 路丽明, 李勤, 郭忠慧, 杨启修, 张嘉敏, 赵俸涌, 王晨, 朱自严. 肿瘤新抗原肽诱导献血者PBMC特异反应性T细胞^*[J]. 临床输血与检验, 2022, 24(5): 565-573.
[9]	周琳, 慈璇, 邵小宝, 王华, 杨圆, 高凤威, 朱培元. 结直肠恶性肿瘤患者围手术期输血和术后感染并发症的相关性研究^*[J]. 临床输血与检验, 2022, 24(4): 416-421.
[10]	梁颖, 伍仕敏. 石墨烯电化学生物传感器在肿瘤检测中的研究进展^*[J]. 临床输血与检验, 2022, 24(4): 539-544.
[11]	鲁大鹏, 王保龙. 血清miRNAs作为潜在肝癌诊断标志物的临床价值研究^*[J]. 临床输血与检验, 2022, 24(3): 343-348.
[12]	邵意涵, 朱培元. 血小板的免疫学特性研究进展^*[J]. 临床输血与检验, 2022, 24(3): 382-391.
[13]	李小薇, 肖军, 雷慧芬, 白晓莹, 孟方园, 李翠莹. 藏、汉族EPAS1基因启动子区DNA甲基化的差异研究^*[J]. 临床输血与检验, 2021, 23(5): 569-573.
[14]	胡婷婷, 王诗铭, 王希文, 海艳秋, 孙婷. 肿瘤患者输注血小板发生不良反应影响因素分析[J]. 临床输血与检验, 2021, 23(4): 464-468.
[15]	蔡梦洁, 梅仁, 戴兰, 沈文红, 傅琤琤, 朱明清. 多发性骨髓瘤循环肿瘤浆细胞的免疫表型特征及其临床意义^*[J]. 临床输血与检验, 2021, 23(4): 478-482.